Gilead Sciences, Inc. today announced new research to be presented at The Liver Meeting® 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 15-19 in San ...
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is excited to announce that its novel oral ketamine analog, Ketamir-2, has shown greater pain ...
Another group received a yet-to-be-approved treatment, while the third took nothing ... The common side effects were headache, flushing, heart palpitations, fast heart rate, nausea, vomiting, ...
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- , (Nasdaq: TVTX) ...